Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Follow-Up Questions
Genocea Biosciences Inc (GNCAQ) の株価収益率はいくらですか？
Genocea Biosciences Inc の株価収益率は 0 です。
Genocea Biosciences Inc のCEOは誰ですか？
Mr. William Clark は Genocea Biosciences Inc の President で、2010 から在籍しています。
GNCAQ の株価パフォーマンスは？
GNCAQ の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Genocea Biosciences Inc の主な事業テーマや業界は？
Genocea Biosciences Inc は Biotechnology 業界、セクターは Health Care に属しています。
